EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes

Kirsa Skov-Jeppesen iD, Charlotte B Christiansen iD, Laura S Hansen, Johanne A Windeløv, Nora Hedbäck, Lærke S Gasbjerg, Morten Hindsø, Maria S Svane iD, Sten Madsbad, Jens J Holst iD, Mette M Rosenkilde, Bolette Hartmann iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Kirsa Skov-Jeppesen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 2, Diabetes Mellitus, Type 2, Bone Remodeling. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dagmar Marshalls Fond, Aase og Ejnar Danielsens Fond, Danish Diabetes Academy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Individuals with type 2 diabetes (T2D) have an increased risk of bone fractures despite normal or increased bone mineral density. The underlying causes are not well understood but may include disturbances in the gut-bone axis, in which both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are regulators of bone turnover. Thus, in healthy fasting participants, both exogenous GIP and GLP-2 acutely reduce bone resorption.

Objective

The objective of this study was to investigate the acute effects of subcutaneously administered GIP and GLP-2 on bone turnover in individuals with T2D.

Methods

We included 10 men with T2D. Participants met fasting in the morning on 3 separate test days and were injected subcutaneously with GIP, GLP-2, or placebo in a randomized crossover design. Blood samples were drawn at baseline and regularly after injections. Bone turnover was estimated by circulating levels of collagen type 1 C-terminal telopeptide (CTX), procollagen type 1 N-terminal propeptide (P1NP), sclerostin, and PTH.

Results

GIP and GLP-2 significantly reduced CTX to (mean ± SEM) 66 ± 7.8% and 74 ± 5.9% of baseline, respectively, compared with after placebo (P = .001). In addition, P1NP and sclerostin increased acutely after GIP whereas a decrease in P1NP was seen after GLP-2. PTH levels decreased to 67 ± 2.5% of baseline after GLP-2 and to only 86 ± 3.4% after GIP.

Conclusion

Subcutaneous GIP and GLP-2 affect CTX and P1NP in individuals with T2D to the same extent as previously demonstrated in healthy individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 2Diabetes Mellitus, Type 2Bone RemodelingCross-Over StudiesHumansMaleMiddle AgedAgedAdultBone Density

Stichwörter der Autor:innen

CTXP1NPbone turnoverglucagon-like peptide-2 (GLP-2)glucose-dependent insulinotropic polypeptide (GIP)gut-bone axis

Substanzen

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 2

Autor:innen und Institutionen

  • Department of Biomedical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, DK-2200 Copenhagen, Denmark.
  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark.
  • Department of Endocrinology, Hvidovre University Hospital, DK-2650 Hvidovre, Denmark.

ORCID-Profile: Kirsa Skov-Jeppesen, Charlotte B Christiansen, Maria S Svane, Jens J Holst, Bolette Hartmann

Förderung

  • Dagmar Marshalls Fond
  • Aase og Ejnar Danielsens Fond
  • Danish Diabetes Academy
  • Novo Nordisk Foundation

Zitieren

APA

Skov-Jeppesen, K., Christiansen, C. B., Hansen, L. S., Windeløv, J. A., Hedbäck, N., Gasbjerg, L. S., Hindsø, M., Svane, M. S., Madsbad, S., Holst, J. J., Rosenkilde, M. M., & Hartmann, B. (2024). Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae022

Vancouver

Skov-Jeppesen K, Christiansen CB, Hansen LS, Windeløv JA, Hedbäck N, Gasbjerg LS, et al. Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae022

BibTeX
@article{SkovJeppesen2024,
  author = {Skov-Jeppesen, Kirsa and Christiansen, Charlotte B and Hansen, Laura S and Windeløv, Johanne A and Hedbäck, Nora and Gasbjerg, Lærke S and Hindsø, Morten and Svane, Maria S and Madsbad, Sten and Holst, Jens J and Rosenkilde, Mette M and Hartmann, Bolette},
  title = {Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae022}
}
Kostenlos starten →